Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-590: Pembrolizumab plus cisplatin and 5-fluorouracil vs placebo plus cisplatin and 5-fluorouracil in advanced/metastatic esophageal carcinoma
jRCT2080223683Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in esophageal cancer, Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenocarcinoma (EAC) and 1 more comparing Pembrolizumab + cisplatin + 5-fluorouracil with Placebo + cisplatin + 5-fluorouracil (2 arms). Started Oct 2017; status: completed.
02
Drugs
03
Conditions
esophageal cancerEsophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080223683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223683.